A Phase 3 interventional study of Amlodipine 5 mg and Valsartan 80 mg in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in 10 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2011-06-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 20th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2008, is one of 53 in phase 3, and was the 93rd registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 965 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 31st largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 137th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
To characterize the safety, tolerability, and efficacy profile of amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 mg (with optional titration to 5/80 mg) and amlodipine 5 mg monotherapy in elderly patients (≥ 65 years of age) with essential hypertension. All three regimens are expected to be well tolerated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed as having hypertension:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
Drug: Amlodipine 5 mg · Drug: Valsartan 80 mg
1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
Drug: Amlodipine 5 mg · Drug: Valsartan 40 mg
1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
Drug: Amlodipine 5 mg · Drug: Placebo
1 capsule amlodipine 5 mg orally once daily
1 capsule valsartan 80 mg orally once daily
1 capsule valsartan 40 mg orally once daily
1 capsule placebo to match valsartan orally once daily
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.
Time frame: Baseline to end of study (Week 8)
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 8
A systolic blood pressure response was defined as a msSBP \< 140 mmHg or ≥ 15 mmHg reduction from baseline at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)
Systolic blood pressure control was defined as a msSBP \< 140 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.
Time frame: End of study (Week 8)
Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
Overall blood pressure control was defined as a msSBP \< 140 mmHg and msDBP \< 90 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.
Time frame: End of study (Week 8)
965 patients were enrolled in the study. Of these, 819 met the criteria for entry into the double-blind phase of the study where efficacy and safety were evaluated.
| Milestone | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| Started | 275 | 272 | 272 |
| Completed | 259 | 260 | 261 |
| Not completed | 16 | 12 | 11 |
| Withdrew: Missing | 1 | 1 | 1 |
| Withdrew: Adverse event | 9 | 4 | 3 |
| Withdrew: Abnormal test procedure result(s) | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 4 |
| Withdrew: Administrative problems | 1 | 3 | 1 |
| Withdrew: Protocol violation | 2 | 2 | 0 |
At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.
| mmHg | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) | -11.1 ± 12.68 | -12.3 ± 13.23 | -6.9 ± 14.00 |
At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.
| mmHg | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) | -4.2 ± 8.04 | -5.3 ± 8.19 | -1.7 ± 7.26 |
A systolic blood pressure response was defined as a msSBP \< 140 mmHg or ≥ 15 mmHg reduction from baseline at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.
| Percentage of patients | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 8 | 46.0 | 48.3 | 34.0 |
Systolic blood pressure control was defined as a msSBP \< 140 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.
| Percentage of patients | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8) | 31.3 | 37.5 | 20.5 |
Overall blood pressure control was defined as a msSBP \< 140 mmHg and msDBP \< 90 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.
| Percentage of patients | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8) | 30.9 | 36.4 | 19.0 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine/Valsartan 5/80 mg | — | 5/274 (1.8%) | 0/274 (0%) |
| Amlodipine/Valsartan 5/40 mg | — | 2/272 (0.7%) | 0/272 (0%) |
| Amlodipine 5 mg | — | 1/272 (0.4%) | 0/272 (0%) |
| Event | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg |
|---|---|---|---|
| TachyarrhythmiaCardiac disorders | 0/274 | 0/272 | 1/272 |
| OphthalmoplegiaEye disorders | 0/274 | 1/272 | 0/272 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/274 | 1/272 | 0/272 |
| Angina pectorisCardiac disorders | 1/274 | 0/272 | 0/272 |
| Atrial fibrillationCardiac disorders | 1/274 | 0/272 | 0/272 |
| Back painMusculoskeletal and connective tissue disorders | 1/274 | 0/272 | 0/272 |
| Lentigo maligna stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/274 | 0/272 | 0/272 |
| Cerebrovascular accidentNervous system disorders | 1/274 | 0/272 | 0/272 |
| Hypertensive crisisVascular disorders | 1/274 | 0/272 | 0/272 |
| Age Continuous(years) | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg | Total |
|---|---|---|---|---|
| Mean | 71.8 ± 5.01 | 71.6 ± 5.38 | 71.4 ± 5.44 | 71.6 ± 5.27 |
| Sex: Female, Male(Participants) | Amlodipine/Valsartan 5/80 mg | Amlodipine/Valsartan 5/40 mg | Amlodipine 5 mg | Total |
|---|---|---|---|---|
| Female | 152 | 138 | 142 | 432 |
| Male | 123 | 134 | 130 | 387 |
The record gives a start of May 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan